Perioperative administration of micronized purified flavonoid fraction in endovascular treatment of varicose disease

Богачев, В. Ю.; Bv, Boldin; Turkin, P. Yu.

doi:10.33529/angio2019214

Cited by 10 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Eight observational studies 28,49,52,53,54,56,100,101 totaling 9683 patients (excluding one observational study 100 ) and four RCTs 67,68,71,74 totaling 2687 patients showed improvement in QOL with MPFF in CVI. One observational study 81 and two RCTs 73,82 showed no significant impact of MPFF on QOL.…”

Section: Improvement In Qolmentioning

confidence: 99%

“…In terms of the use of validated QOL assessment tools, six RCTs 67,68,71,73,74,82 and five observational studies 28,49,52,54,101 used the Chronic Venous Insufficiency Questionnaire, one RCT 37 used the Venous Quality of Life Score (Ve-QOL), one observational study used the Short-Form 12, 81 and one observational study 56 used the Global Index Score. The remaining studies either used an adapted QOL questionnaire 72 or did not report the method of measurement.…”

Section: Improvement In Qolmentioning

confidence: 99%

“…Only the abstract was available for 1 of 14 systematic reviews, 91 for 8 of 33 RCTs, 23,41,46,47,65,67,69,70,82 and for 7 of 19 observational studies, 30,53,57,60,62,64,100 with associated duplicate publications cited. Neither the abstract nor the full manuscript were available for 6 RCTs 25,33,44,79,80,99 (including the unpublished Saveliev RCT) and 1 observational study, 63 with their respective duplicate publications cited.…”

Section: Limitations Of the Current Reviewmentioning

confidence: 99%

See 2 more Smart Citations

Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review

Diendéré

Galanaud

et al. 2021

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

Section: Improvement In Qolmentioning

confidence: 99%

Section: Improvement In Qolmentioning

confidence: 99%

Section: Limitations Of the Current Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review

Diendéré

Galanaud

et al. 2021

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…Отличий в частоте возникновения побочных реакций в зависимости от препарата не было выявлено, и их возникновение объясняется длительной продолжительностью лечения (более 6 мес.) [34,40].…”

Section: доказательная эффективность микронизированной очищенной фрак...unclassified

Current principles of symptomatic treatment of lymphovenous insufficiency

Дунаевская

2023

Ambulatornaya khirurgiya

View full text Add to dashboard Cite

This article provides a review of the current literature on the current principles of symptomatic treatment of lymphovenous insufficiency. Lymphovenous insufficiency is an urgent problem of modern phlebology, the prevalence of this pathology reaches 50% among the world population. Underlying the pathogenesis is venous hypertension, which is caused by venous valve insufficiency, venous outflow obstruction, or combined causes. The use of compression knitwear and symptomatic therapy for lymphovenous insufficiency is an important component of the treatment at the initial stages of the disease — pharmacotherapy based on the use of venoactive drugs. The most promising to date are preparations of the micronized purified flavonide fraction (MPFF) group, which consist of micronized diosmin and flavonides. The use of МОФФ drugs reduces venous hypertension by increasing venous tone, reducing venous capacity, and extensibility of the vessel wall. MPFF also improves lymph conversion by increasing the contractility of the lymphatic capillaries and has an effect on the microcirculation of the vessels of the lower extremities, having an effect on the resistance and permeability of the capillaries. Thus, the use of preparations of the micronized purified fraction of flavonides has a more pronounced effect on the etiology and pathogenesis of the disease, thereby increasing the clinical effect and leading to a more effective result in the treatment of lymphovenous insufficiency. And as presented in this review, drugs containing micronized purified flavonoid fraction are an excellent candidate to be further studied as therapeutic agents for the treatment of lymphovenous insufficiency, because the mechanism of action of the micronized purified flavonoid fraction is directly connected with its pathophysiology and high clinical efficacy.

show abstract

“…Еще в одном мультицентровом исследовании участники отметили значимое снижение болевого синдрома в ближайшем послеоперационном периоде после эндоваскулярного лечения ВБВНК на фоне приема 1000 мг МОФФ в сутки [32].…”

Section: флеботропная эскорт-терапия при инвазивном лечении варикозной болезниunclassified

Current indications for phlebotropic therapy and its duration

Богачев

Болдин

Turkin

et al. 2021

Ambulatornaya khirurgiya

Self Cite

View full text Add to dashboard Cite

Phlebotropic therapy is an important component of the pathogenetic treatment of chronic venous insufficiency (CVI) of the lower extremities. Venoactive drugs, which have proven their effectiveness and safety in a variety of studies, are widely represented in international and Russian clinical guidelines and standards. However, there is no consensus on the regulation of phlebotropic therapy and, above all, its duration in different clinical classes of CVI. In addition, there are no clear indications on the methods of treatment efficacy monitoring, which can be used in real clinical practice. The presented systematized review of the literature data on micronized purified flavonoid fraction not only reveals the possibilities of phlebotropic therapy of different clinical classes and forms of CVI, but also suggests effective regulations for the use of this drug in specific situations. The data concerning the efficacy of phlebotropic therapy in real clinical practice at the initial stages of CVI (C0s-C1s), in the treatment of C2s (varicose superficial veins with venospecific symptoms), C3 (chronic venous edema), C4 (trophic skin disorders), as well as in stages C5-C6 and C6r (venous trophic ulcers) are presented in details. In addition, the results of studies on the use of micronized purified flavonoid fraction in phlebosclerosing treatment are presented. The duration of phlebotropic therapy is in direct relation to the severity of the disease and the response to the ongoing treatment. The important role is played not only by personalization of treatment according to specific symptoms and syndromes, but also, if possible, by objective control of their dynamics.

show abstract

Perioperative administration of micronized purified flavonoid fraction in endovascular treatment of varicose disease

Cited by 10 publications

References 5 publications

Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review

Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review

Current principles of symptomatic treatment of lymphovenous insufficiency

Current indications for phlebotropic therapy and its duration

Contact Info

Product

Resources

About